Xeris Pharmaceuticals stock analysis
Xeris Pharmaceuticals (0A8E) Share Price & Analysis
0A8E Stock Chart & Stats
- Day’s Range
- $16.41 - $16.87
- 52-Week Range
- $5.26 - $16.95
- Previous Close
- $16.61
- Volume
- N/A
- Average Volume (3M)
- 6,146
- Market Cap
- $3.07B
- Enterprise Value
- $1.91B
- Total Cash (Recent Filing)
- $131.08M
- Total Debt (Recent Filing)
- $226.07M
- Price to Earnings (P/E)
- ―
- Beta
- 0.96
- Next Earnings
- Mar 10, 2027 (Est.)
- EPS Estimate
- 0.07
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue Growth
Strong product demand is translating into substantial revenue growth, while the raised 2026 outlook indicates management sees momentum continuing beyond a single quarter. This scale can support greater commercial investment and improve operating leverage as the portfolio expands.
Strong Cash Generation
Positive and growing free cash flow gives Xeris internal funding for commercial expansion, evidence generation, and XP-8121 development. If sustained, this cash generation can reduce reliance on external financing and provide greater flexibility in allocating capital across growth opportunities.
Long-Dated Intellectual Property
Patent protection extending through at least 2043 can preserve KEVEYIS commercial exclusivity and support revenue visibility in a specialty indication. Longer protection also gives Xeris more time to invest in patient identification and support while defending the product from generic competition.
Bears Say
Elevated Balance Sheet Leverage
High leverage remains a material constraint even as equity has improved from prior negative levels. Debt substantially exceeds the equity base, which can limit financial flexibility, increase sensitivity to any slowdown in growth, and restrict the resources available for sustained investment.
GAAP Profitability Is Not Yet Durable
The slight TTM net loss shows that improved operating performance has not yet translated into consistently positive bottom-line earnings. Until profitability becomes durable, results remain more sensitive to operating costs and non-operating items, weakening the reliability of shareholder returns.
Rising Commercial Expenses
Higher commercial and personnel expenses are supporting expansion but create execution risk if revenue growth does not absorb the added cost base. The increased SG&A outlook could restrain operating-margin improvement and make sustained profitability harder while Xeris scales its commercial platform.
Xeris Pharmaceuticals News
0A8E FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
What is Xeris Pharmaceuticals’s market cap?
When is Xeris Pharmaceuticals’s upcoming earnings report date?
How were Xeris Pharmaceuticals’s earnings last quarter?
Is Xeris Pharmaceuticals overvalued?
Does Xeris Pharmaceuticals pay dividends?
What is Xeris Pharmaceuticals’s EPS estimate?
How many shares outstanding does Xeris Pharmaceuticals have?
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Xeris Pharmaceuticals Stock Smart Score
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology. Its current portfolio includes: Gvoke: A ready-to-administer liquid glucagon designed to treat severe hypoglycemia. Keveyis: A therapy addressing hyperkalemic, hypokalemic, and related forms of primary periodic paralysis. Recorlev: A cortisol synthesis inhibitor approved for managing endogenous hypercortisolemia in adult patients with Cushing's syndrome. Beyond its marketed products, the company maintains an active development pipeline. This pipeline seeks to broaden the applications and indications for existing treatments and introduce novel pharmaceuticals leveraging its proprietary XeriSol and XeriJect formulation technology platforms. Founded in 2005, Xeris Biopharma is headquartered in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- John Shannon
- Employees
- 435
- Website
- www.xerispharma.com
- Address
- 1375 West Fulton Street, Chicago, IL, 60607, US
Xeris Pharmaceuticals (0A8E) Earnings & Revenues
0A8E Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with record third-quarter revenue, substantial Recorlev growth, improving Gvoke prescription demand, continued KEVEYIS growth, higher Adjusted EBITDA and net income, strengthened intellectual property, and raised 2026 and 2030 revenue outlooks. The primary negative items were Gvoke net revenue being reduced by a $4 million one-time Medicaid gross-to-net adjustment, ongoing prior authorization requirements for Recorlev, and higher commercial and operating expenses.
View all GB:0A8E earnings summaries0A8E Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 1 | 7 |
| Technical Analysis | 2 | 1 | 7 |
| Moving Averages | 12 | 0 | 0 |














